课题基金 / 基金详情

Therapeutic targeting of ATXN2 for sporadic amyotrophic lateral sclerosis (ALS)

Therapeutic targeting of ATXN2 for sporadic amyotrophic lateral sclerosis (ALS)
ATXN2 治疗散发性肌萎缩侧索硬化症 (ALS) 的靶向治疗
批准号:
9911935
负责人:
Amy Elizabeth Taylor
金额:
$3.75万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-16 至 2023-09-15

项目摘要

项目成果

Amy Elizabeth Taylor的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要 肌萎缩侧索硬化症(ALS)是一种致命的成人起病的神经退行性疾病,有 目前还没有治愈方法,治疗选择也非常有限。出现日益严重的肌肉无力并死亡的患者 在症状出现后3-5年内发生呼吸衰竭。目前,肌萎缩侧索硬化症的研究主要集中在 遗传原因,仅占约10%的病例(家族性),未经任何治疗 其余90%的患者病情发展(零星)。尽管对这种疾病的发病机制一无所知 或疾病的传播,97%的患者有一个共同的病理特征:TDP-43错误定位。TDP-43 是一种必需的RNA结合蛋白,在健康患者中表达于脊髓和皮质运动神经元 原子核。在肌萎缩侧索硬化症中,它错误地定位于细胞质,在那里它形成了不同的磷酸化聚集体,这可能 对神经元有毒性。最近,Aaxin-2(ATXN_2)被确定为TDP-43的潜在调节剂 酵母菌和动物模型的毒性。为了支持这一发现,5%的肌萎缩侧索硬化症患者具有中等长度 基因的PolyQ区域重复扩增,而非神经科对照组的这一比例为2%。此外, 我们的团队和其他人已经证明,无论重复长度如何,ALS患者都表现出 ATXN_2在运动神经元中分布的扰动。综上所述,这些都表明ATXN2可能是 反义寡核苷酸(ASO)的候选治疗潜力,然而,问题仍然是 治疗是否对所有散发性患者都有好处,还是取决于多聚Q长度。 该项目提出了一系列旨在检验ATXN是否具有潜在治疗作用的实验。 直接从疾病患者的人体组织中获得靶点,比较使用和不使用中间体的患者 长度重复扩展。AIMS将通过检查表达来探索靶标的特征和表型 与疾病有关的水平和途径。该提案通过降低级别来检查目标参与度 ATXN2及相关蛋白在该途径中的表达,并探讨其在基因组和蛋白质组特征上的变化 制定一份疾病细胞图谱。最后,它将按顺序验证ATXN-靶向ASO治疗的靶向疗效 以确定可能从治疗中受益的患者子集。 由于肌萎缩侧索硬化症的破坏性,研究重点放在治疗上。 可直接翻译的方式,以加快对现有患者的治疗。这项提议将使 然而,那些可能从ATXN2定向治疗中受益的患者群体仍然持乐观态度 ATXN2的移除将使所有患者受益,而不仅仅是一小部分中等长度的患者 重复着。这份可直接翻译的建议书,以及旧金山最大的ALS诊所的每月患者联系 Diego将在合作研究和临床环境中提供理想的内科科学家培训。
英文摘要
Project Summary / Abstract Amyotrophic lateral sclerosis (ALS) is a fatal, adult onset, neurodegenerative disease for which there is currently no cure and very limited treatment options. Patients present with increasing muscle weakness and die from respiratory failure within 3-5 years post symptom onset. Currently, the majority of ALS research is focused on genetic causes, which account for approximately only 10% of cases (familial), without any treatment developments for the remaining 90% of patients (sporadic). Although nothing is known about the pathogenesis or propagation of disease, 97% of all patients share one pathological hallmark: TDP-43 mislocalization. TDP-43 is an essential RNA binding protein that in healthy patients is expressed in spinal cord and cortical motor neuron nuclei. In ALS it is mislocalized to the cytoplasm where it forms distinct phosphorylated aggregates which may be toxic to the neurons. Recently, Ataxin-2 (ATXN2) has been identified as a potential modulator of TDP-43 toxicity in yeast and animal models. To support this finding, 5% of patients with ALS have intermediate length repeat expansions in the polyQ region of the gene, compared to 2% of non-neurological controls. Furthermore, our group and others have demonstrated that regardless of repeat length, ALS patients demonstrate perturbations in the distribution of ATXN2 in motor neurons. Taken together, these suggest that ATXN2 may be a candidate for antisense oligonucleotide (ASO) therapeutic potential, however, the question remains as to whether therapy would benefit all sporadic patients or be dependent on polyQ length. This project proposes a series of experiments designed to examine ATXN2 as a potential therapeutic target in human tissue directly from patients with disease, comparing patients with and without intermediate length repeat expansions. The aims will explore target characterization and phenotype by examining expression levels and pathways involved in disease. The proposal examines target engagement via knocking down levels of ATXN2 and related proteins in the pathway and exploring the changes in genomic and proteomic signature to develop a disease cellular profile. Lastly, it will verify target efficacy with ATXN2-targeted ASO treatment in order to identify the subset of patients likely to benefit from therapy. Due to the devastating nature of ALS it is imperative that research focus on therapeutic potential in a directly translatable manner in order to expedite treatments for current patients. This proposal will stratify the patient population of those likely to benefit from ATXN2 directed therapy, however, the field remains optimistic that removal of ATXN2 will benefit all patients, not just the small percentage of those with intermediate length repeats. This directly translatable proposal, along with monthly patient contact in the largest ALS clinic in San Diego, will provide ideal physician scientist training in a collaborative research and clinical setting.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Therapeutic targeting of ATXN2 for sporadic amyotrophic lateral sclerosis (ALS)
Therapeutic targeting of ATXN2 for sporadic amyotrophic lateral sclerosis (ALS)
海外基金